574 related articles for article (PubMed ID: 15515136)
1. Characterization of a semi-replicative gene delivery system allowing propagation of complementary defective retroviral vectors.
Trajcevski S; Solly SK; Frisén C; Trenado A; Cosset FL; Klatzmann D
J Gene Med; 2005 Mar; 7(3):276-87. PubMed ID: 15515136
[TBL] [Abstract][Full Text] [Related]
2. VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment.
Qiao J; Moreno J; Sanchez-Perez L; Kottke T; Thompson J; Caruso M; Diaz RM; Vile R
Gene Ther; 2006 Oct; 13(20):1457-70. PubMed ID: 16724095
[TBL] [Abstract][Full Text] [Related]
3. Combined HSV-1 recombinant and amplicon piggyback vectors: replication-competent and defective forms, and therapeutic efficacy for experimental gliomas.
Pechan PA; Herrlinger U; Aghi M; Jacobs A; Breakefield XO
J Gene Med; 1999; 1(3):176-85. PubMed ID: 10738566
[TBL] [Abstract][Full Text] [Related]
4. Highly efficient gene delivery for bladder cancers by intravesically administered replication-competent retroviral vectors.
Kikuchi E; Menendez S; Ozu C; Ohori M; Cordon-Cardo C; Logg CR; Kasahara N; Bochner BH
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4511-8. PubMed ID: 17671137
[TBL] [Abstract][Full Text] [Related]
5. Replicative retroviral vectors for cancer gene therapy.
Solly SK; Trajcevski S; Frisén C; Holzer GW; Nelson E; Clerc B; Abordo-Adesida E; Castro M; Lowenstein P; Klatzmann D
Cancer Gene Ther; 2003 Jan; 10(1):30-9. PubMed ID: 12489026
[TBL] [Abstract][Full Text] [Related]
6. A retroviral packaging cell line for pseudotype vectors based on glioma-infiltrating progenitor cells.
Fischer YH; Miletic H; Giroglou T; Litwak S; Stenzel W; Neumann H; von Laer D
J Gene Med; 2007 May; 9(5):335-44. PubMed ID: 17474071
[TBL] [Abstract][Full Text] [Related]
7. Transgene amplification and persistence after delivery of retroviral vector and packaging functions with E1/E4-deleted adenoviruses.
Torrent C; Jullien C; Klatzmann D; Perricaudet M; Yeh P
Cancer Gene Ther; 2000 Aug; 7(8):1135-44. PubMed ID: 10975674
[TBL] [Abstract][Full Text] [Related]
8. Effects of viral strain, transgene position, and target cell type on replication kinetics, genomic stability, and transgene expression of replication-competent murine leukemia virus-based vectors.
Paar M; Schwab S; Rosenfellner D; Salmons B; Günzburg WH; Renner M; Portsmouth D
J Virol; 2007 Jul; 81(13):6973-83. PubMed ID: 17442710
[TBL] [Abstract][Full Text] [Related]
9. Comparative analyses of transgene delivery and expression in tumors inoculated with a replication-conditional or -defective viral vector.
Ichikawa T; Chiocca EA
Cancer Res; 2001 Jul; 61(14):5336-9. PubMed ID: 11454670
[TBL] [Abstract][Full Text] [Related]
10. Plasmovirus: replication cycle of a novel nonviral/viral vector for gene transfer.
Morozov VA; Noguiez-Hellin P; Laune S; Tamboise E; Salzmann JL; Klatzmann D
Cancer Gene Ther; 1997; 4(5):286-93. PubMed ID: 9345600
[TBL] [Abstract][Full Text] [Related]
11. Construction of new retroviral producer cells from adenoviral and retroviral vectors.
Lin X
Gene Ther; 1998 Sep; 5(9):1251-8. PubMed ID: 9930327
[TBL] [Abstract][Full Text] [Related]
12. Retroviral vector-producing mesenchymal stem cells for targeted suicide cancer gene therapy.
Uchibori R; Okada T; Ito T; Urabe M; Mizukami H; Kume A; Ozawa K
J Gene Med; 2009 May; 11(5):373-81. PubMed ID: 19274675
[TBL] [Abstract][Full Text] [Related]
13. Adenovirus replication-competent vectors (KD1, KD3) complement the cytotoxicity and transgene expression from replication-defective vectors (Ad-GFP, Ad-Luc).
Habib NA; Mitry R; Seth P; Kuppuswamy M; Doronin K; Toth K; Krajcsi P; Tollefson AE; Wold WS
Cancer Gene Ther; 2002 Aug; 9(8):651-4. PubMed ID: 12136425
[TBL] [Abstract][Full Text] [Related]
14. Stable in vivo gene transduction via a novel adenoviral/retroviral chimeric vector.
Feng M; Jackson WH; Goldman CK; Rancourt C; Wang M; Dusing SK; Siegal G; Curiel DT
Nat Biotechnol; 1997 Sep; 15(9):866-70. PubMed ID: 9306401
[TBL] [Abstract][Full Text] [Related]
15. Experimental therapy of allogeneic solid tumors induced in athymic mice with suicide gene-transducing replication-competent foamy virus vectors.
Heinkelein M; Hoffmann U; Lücke M; Imrich H; Müller JG; Meixensberger J; Westphahl M; Kretschmer A; Rethwilm A
Cancer Gene Ther; 2005 Dec; 12(12):947-53. PubMed ID: 15905857
[TBL] [Abstract][Full Text] [Related]
16. Factors affecting long-term expression of a secreted transgene product after intravenous administration of a retroviral vector.
McCormack JE; Edwards W; Sensintaffer J; Lillegren L; Kozloski M; Brumm D; Karavodin L; Jolly DJ; Greengard J
Mol Ther; 2001 Apr; 3(4):516-25. PubMed ID: 11319912
[TBL] [Abstract][Full Text] [Related]
17. Myocardial injury-induced fibroblast proliferation facilitates retroviral-mediated gene transfer to the rat heart in vivo.
Byun J; Huh JE; Park SJ; Jang JE; Suh YL; Lee JS; Gwon HC; Lee WR; Cosset FL; Kim DK
J Gene Med; 2000; 2(1):2-10. PubMed ID: 10765500
[TBL] [Abstract][Full Text] [Related]
18. In vivo retroviral mediated gene transfer into bladder urothelium results in preferential transduction of tumoral cells.
Dumey N; Mongiat-Artus P; Devauchelle P; Lesourd A; Cotard JP; Le Duc A; Marty M; Cussenot O; Cohen-Haguenauer O
Eur Urol; 2005 Feb; 47(2):257-63. PubMed ID: 15661423
[TBL] [Abstract][Full Text] [Related]
19. Replicating retroviral vectors mediating continuous production and secretion of therapeutic gene products from cancer cells.
Finger C; Sun Y; Sanz L; Alvarez-Vallina L; Buchholz CJ; Cichutek K
Cancer Gene Ther; 2005 May; 12(5):464-74. PubMed ID: 15692609
[TBL] [Abstract][Full Text] [Related]
20. Retroviral bicistronic vectors.
Pfützner W
Drug News Perspect; 2008 Nov; 21(9):473-80. PubMed ID: 19180265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
